Verona Pharma plc
VRNA
$58.92
$0.621.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 201.13% | 163.58% | 294.20% | 113.10% | 136.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 201.43% | 168.83% | 467.91% | 33.83% | 42.08% |
| Operating Income | 1.53% | -134.99% | -467.91% | -33.83% | -47.39% |
| Income Before Tax | -80.16% | -191.69% | -721.71% | -51.12% | -36.09% |
| Income Tax Expenses | 15,705.66% | 468.18% | 227.10% | 335.84% | -289.29% |
| Earnings from Continuing Operations | -139.36% | -192.52% | -704.30% | -54.06% | -35.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.36% | -192.52% | -704.30% | -54.06% | -35.22% |
| EBIT | 1.53% | -134.99% | -467.91% | -33.83% | -47.39% |
| EBITDA | 1.84% | -135.58% | -473.21% | -33.56% | -47.51% |
| EPS Basic | -131.69% | -186.37% | -687.57% | -48.31% | -27.24% |
| Normalized Basic EPS | -74.39% | -185.61% | -661.79% | -45.46% | -75.40% |
| EPS Diluted | -110.11% | -186.37% | -687.57% | -48.31% | -51.52% |
| Normalized Diluted EPS | -74.39% | -185.61% | -661.79% | -45.46% | -75.40% |
| Average Basic Shares Outstanding | 3.29% | 2.15% | 2.17% | 3.90% | 6.28% |
| Average Diluted Shares Outstanding | 3.29% | 2.15% | 2.17% | 3.90% | 6.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |